A novel gene signature (TPX2, CDC20, CFHR4, SPP1, and NQO1) from the VM-derived subtypes has been constructed and used to provide valuable clinical references for HCC patients in predicting prognosis and immunotherapy effect. This evidence concerns the gene CFHR4 and hepatocellular carcinoma.